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Abstract
Motor neuron diseases (MND) such as amyotrophic lateral sclerosis and spinal muscular atrophy are devastating,
progressive and ultimately fatal diseases for which there are no effective treatments. Recent evidence from sys-
tematic studies of animal models and human patients suggests that the neuromuscular junction (NMJ) is an
important early target in MND, demonstrating functional and structural abnormalities in advance of pathologi-
cal changes occurring in the motor neuron cell body. The ability to study pathological changes occurring at the
NMJ in humans is therefore likely to be important for furthering our understanding of disease pathogenesis,
and also for designing and testing new therapeutics. However, there are many practical and technical reasons
why it is not possible to visualise or record from NMJs in pre- and early-symptomatic MND patients in vivo.
Other approaches are therefore required. The development of stem cell technologies has opened up the possi-
bility of creating human NMJs in vitro, using pluripotent cells generated from healthy individuals and patients
with MND. This review covers historical attempts to develop mature and functional NMJs in vitro, using co-
cultures of muscle and nerve from animals, and discusses how recent developments in the generation and
specification of human induced pluripotent stem cells provides an opportunity to build on these previous
successes to recapitulate human neuromuscular connectivity in vitro.
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model.
Motor neuron diseases (MND) are a group of relatively com-
mon, and ultimately fatal, neurodegenerative conditions
for which there is presently no cure and few ineffective
treatment options. Amyotrophic lateral sclerosis (ALS) is the
most common form of adult-onset MND, with an incidence
of approximately two per 100 000 (Logroscino et al. 2010),
where degeneration of both upper and lower motor neu-
rons causes progressive paralysis and death within 2–5 years
of diagnosis (Rothstein, 2009). The vast majority of cases are
sporadic, with < 10–15% of cases familial (Schymick et al.
2007). An increasing number of genes have been linked to
both familial and sporadic ALS, including SOD1 (Rosen et al.
1993), FUS (Vance et al. 2009) and TDP-43 (Sreedharan et al.
2008). In contrast to ALS, spinal muscular atrophy (SMA) is a
predominantly childhood form of MND, and is the most
common genetic cause of infant mortality (Lunn & Wang,
2008). Mutations in the survival motor neuron 1 (SMN1)
gene cause progressive paralysis and muscle atrophy, result-
ing from degeneration and loss of lower motor neurons in
the brainstem and spinal cord (Lunn & Wang, 2008). In its
most severe form (type I SMA), disease symptoms are appar-
ent by 6 months old, and the child dies before the age of
2 years (Russman, 2007).
Despite having distinct aetiologies and clinical symptoms,
recent evidence from studies of both ALS and SMA
suggests that early pathological changes occurring in the
most distal part of the lower motor neuron, at the neuro-
muscular junction (NMJ), are a significant common feature
Correspondence
Thomas H. Gillingwater, Euan MacDonald Centre for Motor Neurone
Disease Research, University of Edinburgh, Edinburgh EH8 9XD, UK.
T: +44 (0)131 6503724; F: +44 (0)131 6504193;
E: T.Gillingwater@ed.ac.uk
Accepted for publication 1 November 2011
Article published online 2 December 2011
ª 2011 The Authors
Journal of Anatomy ª 2011 Anatomical Society
J. Anat. (2012) 220, pp122–130 doi: 10.1111/j.1469-7580.2011.01459.x
Journal of Anatomy
of ALS and SMA (Frey et al. 2000; Fischer et al. 2004; Gould
et al. 2006; Murray et al. 2008; Kong et al. 2009). Impor-
tantly, NMJ disruption can be readily identified in MND
mouse models ‘before’ the onset of symptoms (for review,
see Murray et al. 2010a). Thus, the development of experi-
mental systems and technical approaches that allow the
examination of functional and physical synaptic pathology
at the human NMJ are likely to be required in order to
obtain a fuller understanding of the pathophysiology of
MND, and for the development and testing of new
therapeutics.
Unfortunately, many factors contribute to the fact that it
is almost impossible to examine the NMJs of patients with
MND, particularly at early stages of disease. These include
the absence of reliable biomarkers capable of revealing dis-
ease onset as well as late presentation and diagnosis of
patients. In addition, current methods allowing the visuali-
sation of human NMJs (e.g. using light or electron micro-
scopy) require an invasive biopsy procedure and only allow
the examination of pathology at a fixed point in time. Con-
sequently, there are no techniques that will allow repeated
visualisation and ⁄or experimental manipulation of human
NMJs in vivo. The next best solution would be the recrea-
tion of human neuromuscular connectivity ex vivo.
Recent developments have demonstrated that human
induced pluripotent stem cells (iPSCs) have the potential to
be converted into a range of different cell types belonging
to the neuromuscular system, including lower motor neu-
rons (Inoue, 2010). When coupled with the ability to obtain
iPSCs from patients with MND (e.g. Dimos et al. 2008; Ebert
et al. 2009), it raises the possibility that iPSC technologies,
coupled with traditional co-culture techniques, may make it
possible to recreate healthy and diseased human neuromus-
cular connectivity in vitro.
The NMJ in MND
The mammalian NMJ is a cholinergic synapse formed
between a lower motor neuron and a skeletal muscle fibre
(Fig. 1; Sanes & Lichtman, 1999). Four different cell types
are now considered to contribute to the NMJ; the presynap-
tic motor nerve terminal, the skeletal muscle fibre, one or
more non-myelinating terminal Schwann cells, and one or
more NMJ capping cells (known as kranocytes; Court et al.
2008). Importantly, the presence of cell types other than
motor neurons and skeletal muscle at the NMJ should not
be underestimated for normal synaptic form and function.
For example, terminal Schwann cells play a key role in
stabilising the NMJ and coordinating regeneration
responses after injury (Son et al. 1996). Similarly, kranocytes
may also be involved in NMJ maintenance and injury
response (Court et al. 2008).
Historically, it was accepted that ALS pathology occurred
primarily as a result of disturbances in the cell body of
motor neurons, with ubiquitinated accumulations of pro-
teins resulting in death of the cell body. However, recent
evidence suggests that early pathological events occurring
at the NMJ may ultimately be responsible for the early dis-
ruption of neuromuscular function observed in patients
with MND, occurring in advance of pathological changes in
other regions of the motor neuron (Frey et al. 2000; Fischer
et al. 2004; Gould et al. 2006; Murray et al. 2010a). For
example, Frey et al. (2000) showed that there was extensive
denervation of limb muscles in SOD1G93A mice (a commonly
used animal model of ALS) about 40 days before any symp-
toms, such as muscle weakness, were apparent. Fischer
et al. (2004) reported similar observations in SOD1G93A mice,
and also in rare post mortem material from a patient with
ALS who died unexpectedly during the early stages of the
Fig. 1 The NMJ. Upper motor neurons synapse onto lower motor neurons in the spinal cord. Lower motor neurons then send their axons out to
target skeletal musculature via peripheral nerves. Once a lower motor neuron axon has reached its target muscle (magnified box) it will form
neuromuscular synapses with individual muscle fibres. The motor nerve terminal (green) makes up the presynaptic component of the NMJ, and
features numerous synaptic vesicles containing the neurotransmitter acetylcholine. The postsynaptic muscle fibre (orange) is also specialised, with
accumulations of acetylcholine receptors at the motor endplate (red). The motor nerve terminal is insulated by one or more terminal Schwann cells
(blue). A second ‘NMJ capping cell’ – the kranocyte – also overlies the terminal Schwann cell (pink).
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disease – NMJ breakdown was present during pre-symp-
tomatic stages of the disease when no cell death of motor
neuron cell bodies could be detected in the spinal cord
(Fischer et al. 2004). Further experiments in ALS mice dem-
onstrated that deletion of the pro-apoptotic gene Bax from
SOD1G93A mice rescued death of motor neuron cell bodies
in the spinal cord, but did not prevent NMJ breakdown and
only modestly affected disease progression (Gould et al.
2006). Similar evidence demonstrating functional and struc-
tural disturbance of the NMJ in ALS and ALS-like conditions
has been presented from a range of other animal models,
including mice, dogs, zebrafish, Caenorhabditis elegans and
Drosophila (Rich et al. 2002; Ferri et al. 2003; Feiguin et al.
2009; Wang et al. 2009; Ramesh et al. 2010).
Early disruption of NMJs has also been reported in mouse
models of SMA (Cifuentes-Diaz et al. 2002; Kariya et al.
2008; Murray et al. 2008, 2010b; Kong et al. 2009). For
example, Murray et al. (2008) demonstrated that denerva-
tion of NMJs was present in particularly vulnerable muscles
from a mouse model of severe SMA, even at pre-symptom-
atic ages. Subsequent functional studies revealed evidence
of impaired synaptic transmission at the NMJ in SMA mice,
resulting from a reduction in the number of synaptic vesi-
cles present in motor nerve terminals (Kong et al. 2009).
This reduction in synaptic vesicle density could also account
for the widespread muscle weakness observed in SMA
(Kong et al. 2009). Rare post mortem material from patients
with SMA has also revealed disruption of NMJs (Kariya et al.
2008).
In vitro NMJ models
Although the NMJ is a fundamental and early pathological
target in MND, the range of approaches and models avail-
able to study human NMJ pathology are limited. In general,
researchers are restricted to studying human post mortem
material invariably from advanced patients or animal mod-
els that often fail to fully recapitulate the human MND phe-
notype. The development of new experimental approaches
and models that will allow the examination and manipula-
tion of human NMJs is therefore likely to be of significant
benefit for our understanding of disease pathogenesis, dis-
covery and testing of novel treatments. One such approach
that is currently being actively pursued is the development
of in vitro co-culture systems using human iPSCs to generate
cell types contributing to neuromuscular connectivity.
Early attempts to co-culture spinal motor neurons and
skeletal muscle were basic and focused on understanding
NMJ development rather than studying disease. Initially,
the favoured species for neuromuscular myotome co-cul-
tures was Xenopus, as the embryos were easy to collect and
dissect, and the cultures could be maintained at room tem-
perature. Indeed, it was embryonic Xenopus tissue that was
used in the earliest documented co-culture of spinal and
skeletal muscle tissue (Harrison, 1907). In this experiment,
embryonic Xenopus myotomes were removed and the
developing neuromuscular connections were observed in
culture over several days, providing the first evidence that
NMJs could continue to develop as normal under in vitro
conditions (Harrison, 1907). Over the next few decades,
methods for culturing neuromuscular tissue changed very
little. Advances were made in the ability to generate myo-
tome cultures from other species, such as embryonic chick
and rodent tissue (Szepsenwol, 1941). Improvements in elec-
trophysiological techniques also meant that the culture
preparations could be subjected to functional as well as
morphological assays. For example, in 1964 Crain showed
that neuromuscular connections, which had developed in
vitro for several months (Bornstein & Breitbart, 1964), were
capable of neuromuscular transmission (Crain, 1964). How-
ever, the methodology employed in all of these early exper-
iments was limited by the fact that protocols were centred
around removing a section of embryonic spinal cord from
chicks, rodents or Xenopus with developing ganglia and
muscle still attached and undisturbed – the spinal cord and
respective muscle tissue were effectively kept as a myotome
unit (Szepsenwol, 1941; Bornstein & Breitbart, 1964; Crain,
1964).
The next major technical breakthrough came in 1968
when Crain (1968) cultured physically separate (by about
1 mm) explants of rodent skeletal muscle and spinal cord,
and showed that processes extending from the ventral side
of the spinal cord could invade the muscle tissue to form
structural and functional synaptic connections. In the same
year, James and Tresman applied the same co-culture tech-
nique to embryonic chick tissue, and used electron micros-
copy to analyse the morphological aspects of synaptic
connections that were formed. Although the connections
were immature, they revealed the presence of synaptic vesi-
cles as well as putative postsynaptic specialisations (James &
Tresman, 1968). After the discovery that completely sepa-
rate explants could still form immature neuromuscular con-
nections, other co-culture systems were rapidly developed,
such as the use of dissociated cells from chick skeletal mus-
cle and spinal cord (Fischbach, 1970), and monolayer culture
systems also using chick spinal cords and muscle (Shimada
et al. 1969).
In 1970 Peterson and Crain demonstrated that neuromus-
cular connections could be formed not only between
embryonic tissue from different species (specifically
between rat and mouse tissue), but also using adult muscle
tissue and embryonic spinal cord from rodents (Peterson &
Crain, 1970), as well as skeletal muscle tissue from adult
humans and embryonic spinal cord from rodents (Crain
et al. 1970). These cultures were maintained for up to
7 weeks, and electrophysiological data showed that synap-
tic connections formed between rat neurons and human
muscle were functional; stimulation of the rat spinal cord
resulted in action potentials in the muscle (Crain et al.
1970). Histological analysis also revealed accumulations of
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acetylcholinesterase at sites of synaptic contact (Crain et al.
1970). Later adaptations to experimental protocols allowed
researchers to successfully maintain similar co-cultures for
up to 40 weeks (Peterson & Crain, 1972).
The establishment of a reliable protocol for co-culture
led to many groups using in vitro models to study the
effects of human disease on neuromuscular connectivity.
For example, Liveson et al. (1975) studied the effects of
ALS patient sera on co-cultures of embryonic mouse spinal
cord and skeletal muscle. Their finding of no resulting
abnormalities effectively ended a popular theory that a
cytotoxic substance was present in the sera of patients
with ALS (Liveson et al. 1975). Witkowski & Dubowitz
(1975) were the first to culture embryonic mouse spinal
cords with muscle biopsies taken from human patients suf-
fering from a range of neuromuscular conditions, includ-
ing SMA and Duchenne muscular dystrophy. They found
no clear differences between control and diseased muscle
groups, and concluded that any pathology observed in suf-
ferers was not primarily caused by the muscle (Witkowski
& Dubowitz, 1975). However, muscle regeneration was the
focus of this study and so cultures were only kept for a
maximum of 11 weeks (Witkowski & Dubowitz, 1975). A
later study by Peterson et al. (1986) also used human dys-
trophic muscle in co-culture and, when maintained for
more than 4 months, the regenerated muscle did begin to
display pathological features such as myofilament break-
down and cytoplasmic bodies. However, despite these
breakthroughs, the only human tissue that could be used
in nerve ⁄muscle co-cultures was skeletal muscle. The ability
to generate human motor neurons, with or without
disease mutations, only became a possibility with the
advent of stem cell technology (for review, see Marchetto
et al. 2011).
Human stem cell-derived in vitro NMJ models
Human PSCs were first isolated from the inner cell mass of
the blastocyst, the pre-implantation embryo, in 1998 (Thom-
son et al. 1998). These human embryonic stem cells (hESCs)
were micro-manipulated and subsequently grown in culture
by a variety of methods (Xu et al. 2001; Amit et al. 2003,
2004), generating non-transformed, stable and commer-
cially available cell lines. iPSCs, on the other hand, can be
generated from terminally differentiated adult somatic cells
(e.g. dermal fibroblasts), which are then ‘reprogrammed’
through transfection with transcription factors, initially four
in the pioneering study led by Yamanaka (Takahashi et al.
2007; for review, see Amabile & Meissner, 2009). The result-
ing cells are embryonic-like, and possess the capacity to
both self-renew and differentiate into any cell type. By vir-
tue of the fact that they are non-transformed, hESCs poten-
tially represent a more robust in vitro model for studying
human neurodevelopmental processes. However, because
iPSCs can be generated from patients with specific inherited
diseases, the resulting cells represent an unparalleled
opportunity to study human inherited neurodegenerative
diseases (e.g. SMN1 mutations in SMA; Ebert et al. 2009).
Hence, the advent of disease-specific iPSCs has revolution-
ised the prospect for creating in vitro human disease model
systems to study underlying pathobiological processes at a
cellular and molecular level; but also for the consideration
of novel therapeutic strategies (Ebert et al. 2009; Lee et al.
2009).
One of the most important pre-requisites in creating an
accurate and clinically relevant in vitro model system is to
generate the correct, disease-appropriate, cellular subtype.
In vivo, motor neurons develop from highly restricted foci
in the ventral spinal cord (the pMN domain), while sensory
neurons are largely generated more dorsally (Jessell, 2000).
Building on such developmental insights, and those gained
from studies involving mouse embryonic stem cells, much
progress has been made towards generating human motor
neurons from both embryonic and induced pluripotent cells
(Wichterle et al. 2002; Li et al. 2005; Dimos et al. 2008; Hu &
Zhang, 2009; Guo et al. 2010; Marteyn et al. 2011; Patani
et al. 2011). A caudal positional identity is initially induced
in neural precursor cells, usually by exposure to retinoic acid
(Jessel, 2000; Wichterle et al. 2002), although other meth-
ods to generate caudalised ESC-derived neural precursors
and neurons are recognised (Patani et al. 2009, 2011; Peljto
et al. 2010). Next, a ventral positional identity is assigned,
by activation of the sonic hedgehog signalling pathway
(Wichterle et al. 2002; Li et al. 2005). Once neural precursors
have been positionally specified to the ventral spinal cord,
they can be plated down for terminal differentiation. In
vitro, this usually involves a poly-d-lysine(pdl) ⁄ laminin
substrate with concomitant withdrawal of mitogens and
addition of growth factors, including brain-derived neuro-
trophic factor (BDNF), glial-derived neurotrophic factor
(GDNF) and insulin-like growth factor 1. Using this
approach in an adherent culture system, OLIG2-expressing
motor neuron precursors appear at 3 weeks, and markers
of mature motor neurons (such as HB9) appear from 4 to
5 weeks after neural induction from hPSCs (Li et al. 2005).
The generation of spinal motor neurons from stem cells can
then be validated using a range of morphological and func-
tional techniques to identify features specifically associated
with motor neurons, such as the expression of choline ace-
tyl transferase – an enzyme that produces the neurotrans-
mitter acetylcholine.
To date, a large number of studies using iPSCs have
focussed on deriving motor neurons, but have not
addressed the issue of which particular subtype is being
generated. Two contemporaneous recent studies using
mouse (Peljto et al. 2010) and human iPSCs (Patani et al.
2011) have begun to unravel the developmental logic of
motor neuronal subtype diversification. Such studies raise
the prospect of studying motor neuron subtype selective
vulnerability, which is known to exist in MND (Murray et al.
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2008; Kanning et al. 2010). Furthermore, the NMJs formed
by distinct subtypes of motor neurons may themselves dis-
play differential vulnerability – raising important experi-
mental questions around modelling MND pathogenesis
using intact NMJs rather than just isolated motor neuronal
subtypes.
A number of groups have already attempted to create
NMJs in vitro using human stem cells. However, they have
had limited success, producing only immature points of con-
tact between neurite tips and myotubes. One of the first
studies to attempt to co-culture stem cell-derived motor
neurons with skeletal muscle was performed by Li et al.
(2005). In this study, motor neuron progenitor cells were co-
cultured with the murine myoblast cell line C2C12 (Li et al.
2005). The cultures were maintained for up to 3 weeks,
during which the motor neuron progenitor cells matured
into motor neurons and extended neurites (Li et al. 2005).
Co-cultures were stained with the synaptic marker synapsin,
and a-bungarotoxin was used to label acetylcholine recep-
tors. This analysis revealed that clusters of acetylcholine
receptors were formed on myotubes where they were con-
tacted by neurite processes (Li et al. 2005). Singh Roy et al.
(2005) also attempted to generate NMJs in vitro using a
modified version of the motor neuron differentiation pro-
tocol outlined by Li et al. (2005). Singh Roy et al. (2005)
used human stem cells that had been genetically modified
to express green fluorescent protein under the motor neu-
ron-specific promoter, HB9. After differentiation, these
motor neurons could be isolated from other cell types by
fluorescence-activated cell sorting, resulting in a pure motor
neuron population. In this study, rather than using a muscle
cell line, NMJs were formed with a primary culture of disso-
ciated neonatal rat skeletal muscle (Singh Roy et al. 2005).
As in the Li et al. (2005) study, synaptic vesicle-associated
protein SV2 clusters were found to co-localise with acetyl-
choline receptors on myotubes, indicating synapse forma-
tion (Singh Roy et al. 2005). No clusters of acetylcholine
were observed on skeletal muscle fibres cultured without
motor neurons, implying that receptor clustering was
induced by the presence of motor neurons (Singh Roy et al.
2005).
In 2010, Guo et al. (2010) reported further developments
in methodologies for developing and analysing stem cell-
derived motor neurons co-cultured with skeletal muscle.
Motor neurons were again derived from human stem cells
and were cultured with dissociated skeletal muscle fibres
from embryonic rats. However, Guo and colleagues gener-
ated a pure muscle culture, devoid of other cell types. Co-
cultures were maintained for 4 days in media designed to
support motor neuron maturation and survival then, after
4 days, the media was switched to a simpler NbActiv4
media (Guo et al. 2010). NbActiv4 does not contain trophic
factors, such as BDNF or GDNF, which support axonal
extension and survival but have also been shown to down-
regulate production of agrin – a key molecule involved in
inducing the clustering of acetylcholine receptors at the
developing NMJ (Peng et al. 2003). Co-cultures were main-
tained for a maximum of 10 days before staining for
neuronal-specific cytoskeletal element b-III-tubulin and
acetylcholine receptors (Guo et al. 2010). Staining revealed
neurites overlying muscle cells expressing clusters of acetyl-
choline receptors, similar to those reported previously (Guo
et al. 2010). A Glut–Curare assay was also used to assess the
functional capabilities of their in vitro NMJs. When gluta-
mine was added to their co-cultures (thereby stimulating
motor neurons), the number of contracting muscle cells
increased, and this was reduced to baseline levels when
curare was applied, implying that the points of synaptic
contact were capable of synaptic transmission (Guo et al.
2010).
Recently, Patani and colleagues successfully generated
medial motor column motor neurons from human stem
cells using a retinoid independent protocol. Resulting
motor neurons had preserved capacity to establish imma-
ture synaptic connections with skeletal muscle: a co-culture
with C2C12 myotubes revealed that the stem cell-derived
motor neurons were capable of inducing acetylcholine
receptor clustering on myotubes after 12 days in culture
(Patani et al. 2011).
The first disease-specific human motor neuron–muscle
co-cultures have recently been attempted. For example,
Marteyn et al. (2011) generated motor neurons from
human embryos with myotonic dystrophy type 1. It was
noted that motor neurons generated from affected
patients displayed increased neurite outgrowth compared
with identically cultured motor neurons from non-affected
individuals, so a co-culture approach was used to determine
whether the altered neurite outgrowth might also affect
synaptogenesis at the NMJ (Marteyn et al. 2011). Here, a
human muscle cell line, Mu2bR3, was used in the co-culture,
which was maintained for up to 16 days and then stained
for the pan-neuronal marker TuJ1 and acetylcholine recep-
tors using a-bungarotoxin (Marteyn et al. 2011). From these
co-culture experiments, the authors observed a reduced
number of points of contact in the disease-specific motor
neurons compared with the wild-type motor neurons,
implying that the disease-specific motor neurons have a
reduced ability to form NMJs (Marteyn et al. 2011).
Puatative synapses or mature human NMJs?
Despite initial successes in developing co-cultures of human
motor neurons and muscle to generate NMJs in culture,
stem cell-derived NMJs remain immature and unstable in
comparison to the NMJs previously established using tissues
from other species or NMJs in vivo (Fig. 2). For example,
one of the most striking differences between the recent
stem cell-derived co-cultures and historical co-cultures using
animal tissues is the length of time that the cells could be
maintained in vitro. Peterson & Crain (1972) co-cultured
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muscle and rodent spinal cord for more than 40 weeks,
whereas co-cultures using stem cell-derived motor neurons
have not been successful beyond a 3-week period. This issue
mainly arises due to differences in cell culture media
requirements associated with using stem cell-derived motor
neurons. Human motor neurons derived from stem cells are
notoriously difficult to culture and require a complex media
full of growth and trophic factors, several of which are not
ideal for long-term maintenance of skeletal muscle cells.
One possible solution to this may be to use compartmenta-
lised co-cultures. Keeping each cell type isolated in its opti-
mal culture media would likely mean increased cell survival
and could therefore contribute to increasing the length of
time co-cultures can be maintained for, and therefore the
maturity of NMJs formed.
One other major factor that is likely to require addressing
in order to successfully develop in vitro NMJ models using
stem cell-derived motor neurons concerns the presence of
other supporting cell types, including terminal Schwann
cells and kranocytes (see above). Such cells types are known
to play important roles in supporting NMJs in vivo (Koirala
et al. 2003; Court et al. 2008; Feng & Ko, 2008), and would
have been present in many of the historical co-culture
experiments (although they were never specifically exam-
ined). In contrast, most recent co-cultures using stem cell-
derived motor neurons have used muscle cell lines for the
skeletal muscle component of the co-culture (e.g. Li et al.
2005; Marteyn et al. 2011; Patani et al. 2011). This may have
had a negative effect on synaptogenesis and ⁄or synaptic
maturation. Therefore, the addition of potentially support-
ive cells, such as Schwann cells, to co-cultures may enhance
synaptogenesis and maintain any putative synapses that do
form.
Finally, it should be noted that to create a ‘real’ human
NMJ in vitro, both co-culture components must be human
in origin and, for disease studies, both cell types must carry
the disease mutation. And yet, all recent co-cultures using
human stem cell-derived motor neurons have either been
xeno-cultures or have used primary muscle cell lines, primar-
ily because they are readily obtained and easy to manage.
However, it is possible to create human skeletal muscle
from stem cells (Kim et al. 2005; Barberi et al. 2007).
Attempts to develop NMJs from co-cultures of motor neu-
rons and skeletal muscle both derived from stem cells will
therefore be required. The successful development of such
an approach would make it possible to address fundamen-
tal questions about the roles of nerve and muscle in MND
pathogenesis. For example, there is much controversy over
whether loss of presynaptic inputs at the NMJ (due to path-
ological changes in lower motor neurons) indirectly leads to
muscle atrophy, or whether skeletal muscle is intrinsically
vulnerable to low levels of SMN protein in SMA (Henderson
et al. 1987; Braun et al. 1995; Gavrilina et al. 2008; Mutsaers
et al. 2011). Similar questions are also being raised with
regards to ALS pathogenesis (Miller et al. 2006; Wong &
Martin, 2010).
A
B C
Fig. 2 Comparison of in vitro and in vivo
immature NMJs. (A) Human motor neurons
derived from stem cells stained with b-III-
tubulin (green; arrowhead) extending axons
with growth cones (arrow) towards C2C12
myotubes (red) in culture (blue = TOPRO-
labelled nuclei; TM Wishart and TH
Gillingwater, Unpublished data). (B) High-
magnification image of a cluster (arrow) of
acetylcholine receptors (red) on a C2C12
myotube being induced by an incoming axon
growth cone from a stem cell-derived motor
neuron (green; panel reproduced with
permission from Patani et al. (2011)). (C) In
vivo immature NMJs from a neonatal mouse.
Acetylcholine receptors (red) form large
plaques (arrow) on muscle fibres that are
covered completely by the presynaptic axon
terminal (green). In vivo immature NMJs are
polyinnervated (arrowheads) and, over time,
these excess innervations are pruned in a
process known as synaptic elimination. Note
how neuromuscular junctions formed in vivo
(C) are significantly more developed (even at
such immature stages of growth) than
comparable putative NMJs formed using
in vitro co-culture systems (A and B).
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Conclusions
The ability to use human iPSCs to model early MND patho-
genesis at the NMJ would be extremely valuable to MND
research. Such models would answer fundamental ques-
tions about the nature and mechanisms of some of the
earliest events occurring across a range of different forms
of MND, and would also be useful for rapid evaluation of
the therapeutic effectiveness of new and existing treat-
ment strategies. Early attempts to recreate human neuro-
muscular connectivity using iPSCs have been relatively
successful, although there are numerous technical hurdles
that will need to be overcome if the approach is going to
yield mature NMJs in vitro. The rapid developments occur-
ring in the field of stem cell biology suggest that the
major technical hurdles identified will eventually be sur-
mounted, allowing in vitro human NMJ preparations to
become routinely available to a large number of research
laboratories.
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